Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase 3 randomized double-blind placebo-controlled study of vortioxetine in Japanese adolescents with major depressive disorder
jRCT2031250396Phase 3Recruiting
- Sponsor
- Takeda
- Start
- Oct 2025
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial in major depressive disorder (MDD) comparing Vortioxetine with Placebo (2 arms). Primary endpoint: Change from baseline in CDRS-R total score. Started Oct 2025; status: recruiting.
02
Drugs
vortioxetine
03
Conditions
major depressive disorder (MDD)
Beyond the preview
Go deeper on jRCT2031250396.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on jRCT2031250396.